Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis

Vaccine

Volumn 19, Issue 28-29, 2001, Pages 3834-3842

  Hanlon, C A ^a   DeMattos, C A ^a   DeMattos, C C ^a   Niezgoda, M ^a   Hooper, D C ^b   Koprowski, H ^b   Notkins, A ^c   Rupprecht, C E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Human monoclonal antibodies; Lyssaviruses; Rabies

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; IMOGAM; RABIES IMMUNOGLOBULIN; RABIES VIRUS NEUTRALIZING HUMAN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAT; CONTROLLED STUDY; DRUG SCREENING; EXPOSURE; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; RABIES VIRUS; SYRIAN HAMSTER; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHIROPTERA; CRICETINAE; FEMALE; HUMANS; LYSSAVIRUS; MESOCRICETUS; NEUTRALIZATION TESTS; RABIES; RABIES VIRUS; UNITED STATES;

EID: 0035898947     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00135-9     Document Type: Article

References (60)

1. Rationale and prospects for rabies elimination in developing countries
2. Rabies
3. Human rabies prevention-United States, 1999. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
4. World Health Organization expert committee on rabies. 8th report
5. Prevention of human rabies: Treatment of persons bitten by rabid wolves in Iran
6. Successful protection of humans exposed to rabies infection: Postexposure treatment with the human diploid cell vaccine and antirabies serum
7. Use of serum and vaccine in combination for prophylaxis following exposure to rabies
8. Human rabies after late administration of purified chicken embryo cell (PCEC) vaccine without hyperimmune serum
9. Analysis of human rabies cases despite vaccination
10. Failure of protection of tissue-culture rabies vaccines in postexposure treatment in Thailand - A review
11. Failure of rabies postexposure treatment in Thailand
12. Partial recovery from rabies in a nine-year-old boy
13. Current and future immunoprophylaxis against human rabies: Reduction of treatment failures and errors
14. Failure of postexposure treatment of rabies in children
15. Additional reports of failure to respond to treatment after rabies exposure in Thailand
16. Heterologous antisera and antivenins are essential biologicals: Perspectives on a worldwide crisis
17. A clinical evaluation of a new heat-treated human rabies immune globulin
18. Update: Raccoon rabies epizootic - United States and Canada, 1999
19. Human rabies postexposure prophylaxis during a raccoon rabies epizootic in New York, 1993 and 1994
20. Rabies surveillance in the United States during 1998
21. Mass human exposure to rabies in New Hampshire: Exposures, treatment, and cost
22. Large-scale human exposures to rabid or presumed rabid animals in the United States: 22 Cases
23. Mass treatment of humans who drank unpasteurized milk from rabid cows - Massachusetts, 1996-1998
24. Public health dispatch: Multiple human exposures to a rabid bear cub at a petting zoo and barnwarming - Iowa, August, 1999
25. Rabies virus
26. Special series - Recommendations of a national working group on prevention and control of rabies in the United States, Article II: Laboratory diagnosis of rabies
27. Special series - Recommendations of a national working group on prevention and control of rabies in the United States, Article III: Rabies in wildlife
28. Causes, costs and estimates of rabies postexposure prophylaxis treatments in the United States
29. Development of orphan vaccines: An industry perspective
30. Encephalitis caused by a Lyssavirus in fruit bats in Australia
31. Characterization of a novel lyssavirus isolated from Pteropid bats in Australia
32. Purified equine rabies immune globulin: A safe and affordable alternative to human rabies immune globulin
33. Equine rabies immune globulin: A product with an undeserved poor reputation
34. Incidence of reactions to antirabies horse serum
35. A new generation of purified, heat-treated equine rabies immune globulin: Results of a comparative sham post-exposure trial using Vero-cell rabies vaccine
36. Special series - Recommendations of a national working group on prevention and control of rabies in the United States, Article I: Prevention and education regarding rabies in human beings
37. Capture of human monoclonal antibodies from cell culture supernatant by ion exchange media exhibiting high charge density
38. Genetically engineered antibodies in gene transfer and gene therapy
39. Cell hybridization, hybridomas, and human hybridomas
40. The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure
41. A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody
42. Molecular epidemiology of rabies in the United States: Reemergence of a classical neurotropic agent
43. The mouse inoculation test
44. Epidemiology of human rabies in the United States, 1980 to 1996
45. Human diploid cell culture rabies vaccine (HDCV) and purified chick embryo cell culture rabies vaccine (PCECV) both confer protective immunity against infection with the silver-haired bat rabies virus strain (SHBRV)
46. Biological characterization of human monoclonal antibodies to rabies virus
47. Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein
48. A rabies-specific human monoclonal antibody that protects mice against lethal rabies
49. Passive immunoprophylaxis with human monoclonal antibodies
50. Development of human monoclonal antibodies to rabies
51. Production of human monoclonal antibodies against rabies virus
52. Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies
53. Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies
54. Human rabies immune globulin
55. Rabies immune globulin of human origin: Preparation and dosage determination of non-exposed volunteer subjects
56. Postexposure rabies prophylaxis with human rabies immune globulin
57. Clonal analysis of a human antibody response: Quantification of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus
58. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine
59. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu + by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins